459 filings
Page 7 of 23
6-K
e1ft40iisv9zf336e kv
18 Jan 22
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft
6:19am
6-K
m63wkhb0j1a fyy7fqh
12 Jan 22
HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
6:12am
6-K
jif n9rrvdy2
10 Jan 22
Current report (foreign)
6:11am
6-K
o9xn6dhe3dme
3 Jan 22
Current report (foreign)
6:09am
6-K
57eehuq
20 Dec 21
Current report (foreign)
6:07am
6-K
jhqj2n4mxlpnvly
15 Dec 21
Grant of Share Options under Share Option Scheme and Awards under
6:11am
6-K
bemvldho1ro55t5xwy
14 Dec 21
HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting
6:12am
6-K
xg7mmh2siijaenn5p
10 Dec 21
HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting
6:10am
6-K
aq8v2dr5qn
6 Dec 21
HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
6:11am
6-K
9gg rl20khfwuvvnt1
3 Dec 21
HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China
6:10am
6-K
xavxh6e eeo
30 Nov 21
Current report (foreign)
6:07am
6-K
tbpiyf71hosh 77
24 Nov 21
Current report (foreign)
6:13am
6-K
3e1vczhoa4twa0hkjhn
8 Nov 21
HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting
6:08am
6-K
ushmvwb
1 Nov 21
Current report (foreign)
6:41am
6-K
kk29a0a4g c96rv
29 Oct 21
Current report (foreign)
6:41am
6-K
rsrosmy7 wj
28 Oct 21
Current report (foreign)
6:24am
6-K
fzng1k
20 Oct 21
Grant of Awards under Long Term Incentive Plan
6:14am
6-K
btkaznzfotqs6 hdusz
30 Sep 21
Current report (foreign)
6:19am
6-K
t0cv1ggchaqvbrflfau
29 Sep 21
HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture
6:39am
6-K
8j1kr
21 Sep 21
Current report (foreign)
6:10am